“Neonatal hemochromatosis”: A re‐vision
A. S. Knisely, Diego Vergani – 23 May 2010
Personalized medicine in hepatitis C: From genome‐wide association studies to clinical practice
Hermann E. Wasmuth, Ralf Weiskirchen – 23 May 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin
Moises Diago, Mitchell L. Shiffman, Jean‐Pierre Bronowicki, Stefan Zeuzem, Maribel Rodriguez‐Torres, Stephen C. Pappas, Andreas Tietz, David R. Nelson – 23 May 2010 – The objective of this analysis was to compare sustained virological response (SVR) and relapse rates in patients with a rapid virological response (RVR, HCV RNA <50 IU/mL at week 4) randomized to 24 or 16 weeks of treatment with peginterferon alfa‐2a (40KD) 180 μg/week plus ribavirin 800 mg/day in the multinational ACCELERATE study.
A young woman with a large mass in the right hepatic lobe
Florian Grabellus, Knut M. Nowak – 23 May 2010
Low levels of 25‐hydroxyvitamin D3 in children with biopsy‐proven nonalcoholic fatty liver disease
Melania Manco, Paolo Ciampalini, Valerio Nobili – 23 May 2010
Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro
Jun Yu, Bo Shen, Eagle S. H. Chu, Narci Teoh, Kin‐Fai Cheung, Chung‐Wah Wu, Shiyan Wang, Cleo N. Y. Lam, Hai Feng, Junhong Zhao, Alfred S. L. Cheng, Ka‐Fai To, Henry L. Y. Chan, Joseph J. Y. Sung – 23 May 2010 – Although peroxisome proliferator‐activated receptor gamma (PPARγ) agonist have been shown to inhibit hepatocellular carcinoma (HCC) development, the role of PPARγ in hepatocarcinogenesis remains unclear. We investigated the therapeutic efficacy of PPARγ against HCC.
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical‐hemodynamic correlation study
Vincenzo La Mura, Juan G. Abraldes, Annalisa Berzigotti, Eva Erice, Alexandra Flores‐Arroyo, Juan Carlos García‐Pagán, Jaime Bosch – 23 May 2010 – Hepatic venous pressure gradient (HVPG), the difference between wedge and free hepatic venous pressure, is the preferred method for estimating portal pressure. However, it has been suggested that hepatic atrial pressure gradient (HAPG)—the gradient between wedge hepatic venous pressure and right atrial pressure (RAP)—might better reflect variceal hemodynamics.
Hepatocellular carcinoma: Sorafenib before liver transplantation?
Alain Braillon – 23 May 2010
Nurse‐administered propofol sedation: Differences in perspective
David Frank Dies – 23 May 2010
Sustained virologic response prevents the development of esophageal varices in compensated, Child‐Pugh class A hepatitis C virus–induced cirrhosis. A 12‐year prospective follow‐up study
Savino Bruno, Andrea Crosignani, Corinna Facciotto, Sonia Rossi, Luigi Roffi, Alessandro Redaelli, Roberto de Franchis, Piero Luigi Almasio, Patrick Maisonneuve – 23 May 2010 – The incidence of de novo development of esophageal varices (EV) in patients with compensated liver cirrhosis has been determined by few studies in the short term and never in the long term.